Knight Therapeutics Inc.
GUD.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 49.11% | 330.74% | 69.83% | -699.19% | -80.15% |
| Total Depreciation and Amortization | 15.16% | -21.62% | 47.05% | 8.69% | -13.37% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 457.32% | -111.49% | -1.84% | 462.88% | 112.63% |
| Change in Net Operating Assets | -30.51% | 202.56% | -188.07% | 216.87% | 7.90% |
| Cash from Operations | 16.99% | 239.00% | -49.59% | 472.40% | 143.68% |
| Capital Expenditure | -560.33% | -21.67% | 33.56% | -72.41% | 35.03% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -70.73% |
| Cash Acquisitions | -- | 100.00% | 97.00% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 439.36% | -283.18% | -64.42% | -80.16% | 71.10% |
| Cash from Investing | 329.24% | -222.11% | 98.61% | -427.06% | 73.61% |
| Total Debt Issued | -- | -- | -- | 5,947.21% | 233.15% |
| Total Debt Repaid | 58.00% | -495.71% | 91.03% | -1,963.55% | 66.00% |
| Issuance of Common Stock | -15.79% | 5.56% | -65.29% | 218.42% | -18.57% |
| Repurchase of Common Stock | -174.48% | -- | -- | 99.82% | 35.05% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 78.01% | -188.00% | 66.48% | -437.43% | 80.53% |
| Cash from Financing | 38.61% | -481.81% | -111.68% | 1,221.65% | 70.15% |
| Foreign Exchange rate Adjustments | 289.34% | -174.75% | 129.63% | -547.73% | -57.54% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 683.71% | -232.06% | 111.88% | -211.14% | 392.20% |